Gland Pharma Limited - Conclusion of US FDA Inspection at Dundigal Facility, Hyderabad

The United States Food and Drug Administration (US FDA) has conducted Good Manufacturing Practice (GMP) Inspection at Gland Pharma Limited's Dundigal Facility at Hyderabad between 03rd July, 2023 and 14th July, 2023.

The inspection was concluded with ONE (1) 483 Observation. The corrective and preventive actions for this observation will be submitted to the US FDA within the stipulated period. The observation issued is neither a repeated observation nor related to data integrity.

Shares of Gland Pharma Limited was last trading in BSE at Rs. 1105.10 as compared to the previous close of Rs. 1092.20. The total number of shares traded during the day was 11646 in over 883 trades.

The stock hit an intraday high of Rs. 1109.90 and intraday low of 1087.00. The net turnover during the day was Rs. 12816497.00.

Source : Equity Bulls

Keywords

GlandPharma INE068V01023 USFDA GMPInspection DundigalFacility Hyderabad